Alpine Immune Sciences Inc.

05/24/2022 | Press release | Distributed by Public on 05/24/2022 06:23

FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab - Form 8-K